Advertisement

Topics

Motif Bio secures £10m to support antibiotic commercialization efforts

10:57 EDT 17 May 2018 | in-PharmaTechnologis

Motif Bio plc has secured Â10m ($14m) to support the potential commercialization of its lead candidate â iclaprim â which was granted FDA fast-track status in 2015.

Original Article: Motif Bio secures £10m to support antibiotic commercialization efforts

NEXT ARTICLE

More From BioPortfolio on "Motif Bio secures £10m to support antibiotic commercialization efforts"

Advertisement
Quick Search
Advertisement
Advertisement